The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Open accessAbstract
Topoisomerase poisons are chemotherapeutic agents that are used extensively for treating human malignancies. These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse. Using a pool-based RNAi screening approach and a well characterized mouse model of lymphoma, we explored the genetic basis for heterogeneous responses to topoisomerase poisons in vitro and in vivo . These experiments identified Top2A expression levels as major determinants of response to the topoisomerase 2 poison doxorubicin and showed that suppression of Top2A produces resistance to doxorubicin in vitro and in vivo . Analogously, using a targeted RNAi approach, we demonstrated that suppression of Top1 produces resistance to the topoisomerase 1 poison camptothecin yet hypersensitizes cancer cells to doxorubicin. Importantly, lymphomas relapsing after treatment display spontaneous changes in topoisomerase levels as predicted by in vitro gene knockdown studies. These results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Self-citationp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationCamptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Self-citationThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Isolation and expression of a complementary DNA that confers multidrug resistance
Gros, P., Neriah, Y. B., Croop, J. M., & Housman, D. E. (1986) · Nature · doi:10.1038/323728a0 · Cited by 797
Strasser, A. (1994) · Cell · doi:10.1016/0092-8674(94)90201-1 · Cited by 666
Second-generation shRNA libraries covering the mouse and human genomes
Silva, J. M., Li, M. Z., Chang, K., Ge, W., Golding, M. C., Rickles, R. J., Siolas, D., Hu, G., Paddison, P. J., Schlabach, M. R., et al. (2005) · Nature Genetics · doi:10.1038/ng1650 · Cited by 622
Self-citationProbing tumor phenotypes using stable and regulated synthetic microRNA precursors
Dickins, R. A., Hemann, M. T., Zilfou, J. T., Simpson, D. R., Ibarra, I., Hannon, G. J., & Lowe, S. W. (2005) · Nature Genetics · doi:10.1038/ng1651 · Cited by 524
Self-citationDNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss, J., & Wang, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7501 · Cited by 499
Dissecting p53 tumor suppressor functions in vivo
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00047-8 · Cited by 485
Self-citationSynthetic lethal screen identification of chemosensitizer loci in cancer cells
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., et al. (2007) · Nature · doi:10.1038/nature05697 · Cited by 474
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
Self-citationUemura, T., & Yanagida, M. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02040.x · Cited by 448
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Self-citationDesign of a genome-wide siRNA library using an artificial neural network
Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1118 · Cited by 386
Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
Fortune, J. M., & Osheroff, N. (2000) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(00)64006-0 · Cited by 366
Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., & Lowe, S. W. (2003) · Nature Genetics · doi:10.1038/ng1091 · Cited by 354
Self-citationRottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Genetic analysis of chemoresistance in primary murine lymphomas
Schmitt, C. A., Rosenthal, C. T., & Lowe, S. W. (2000) · Nature Medicine · doi:10.1038/79542 · Cited by 278
Self-citationTanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J., & Bergh, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9264 · Cited by 251
Utilizing RNA interference to enhance cancer drug discovery
Iorns, E., Lord, C. J., Turner, N., & Ashworth, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2355 · Cited by 251
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 189
Targeted Disruption of the Mouse Topoisomerase I Gene by Camptothecin Selection
Morham, S. G., Kluckman, K. D., Voulomanos, N., & Smithies, O. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6804 · Cited by 187
Suppression of tumorigenesis by the p53 target PUMA
Hemann, M. T., Zilfou, J. T., Zhao, Z., Burgess, D. J., Hannon, G. J., & Lowe, S. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403286101 · Cited by 179
Self-citationOxidative stress is the new stress
Gingrich, J. A. (2005) · Nature Medicine · doi:10.1038/nm1205-1281 · Cited by 163
Gudkov, A. V., Zelnick, C. R., Kazarov, A. R., Thimmapaya, R., Suttle, D. P., Beck, W. T., & Roninson, I. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3231 · Cited by 136
Akimitsu, N., Adachi, N., Hirai, H., Hossain, M. S., Hamamoto, H., Kobayashi, M., Aratani, Y., Koyama, H., & Sekimizu, K. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00643.x · Cited by 94
Mano, M. S., Rosa, D. D., de Azambuja, E., Ismael, G., & Durbecq, V. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.10.001 · Cited by 76
Witt, A. E., Hines, L. M., Collins, N. L., Hu, Y., Gunawardane, R. N., Moreira, D., Raphael, J., Jepson, D., Koundinya, M., Rolfs, A., et al. (2006) · Journal of Proteome Research · doi:10.1021/pr050395r · Cited by 75
Yu, Q., Rose, J. H. L., Zhang, H., & Pommier, Y. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02756-9 · Cited by 72
Mukhopadhyay, U. K., Senderowicz, A. M., & Ferbeyre, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2502 · Cited by 56
Characterization of the Topoisomerase I Locus in Human Colorectal Cancer
Boonsong, A., Marsh, S., Rooney, P. H., Stevenson, D. A. J., Cassidy, J., & McLeod, H. L. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00242-9 · Cited by 29
Cited by
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Metadata
- Authors
- Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-07
- Volume
- 105
- Issue
- 26
- Pages
- 9053-9058
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2114800396
- Cited by
- 300
- References
- 38
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.